Mazdutide

A dual GLP-1/glucagon receptor co-agonist, in the same mechanistic class as survodutide; reduces appetite and increases energy expenditure via combined incretin and glucagon receptor activation.

Mechanism of action from published research — how the molecule behaves, not a claim about any product or any human-use effect.

Studied for obesity/weight management and type-2 diabetes glycemic control.

• Weight & metabolicStudied in weight, appetite, blood-sugar, and fat-metabolism research.

In clinical trials in the US (Phase 2); approved in China by the NMPA (2025-2026) for weight management and glycemic control, but not FDA-approved.

Where the science stands — an approved drug is not the same as the research-grade material a vendor sells, which is unregulated regardless.

• Independent purity. Look for a third-party COA (Janoshik or MZ) showing a measured purity — not just a number the vendor typed.
• Batch match. The strongest evidence is a certificate for the exact batch you’ll receive, attributed to this vendor — check the cross-verification on the listing.
• Vendor reputation. See how the vendor is talked about in the community before trusting a new name.

Research context only — VialGrade never gives dosing, medical, or human-use guidance.